Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 7921 AL 7935

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease

Cline EN, Antwi-Berko D, Sundell K, Johnson E, Hyland M, Zhang H, Vanderstichele H, Kaplow J, Dean RA, Stoops E, Vanmechelen E, Koel-Simmelink MJA, Teunissen CE, Sethuraman G, Feaster T, Siemers E, Jerecic J.

J Prev Alzheimers Dis. 2025 Apr;12(4):100082. doi: 10.1016/j.tjpad.2025.100082. Epub 2025 Feb 17.

Mesenchymal Stem Cell-Derived Extracellular Vesicles in Alzheimer's Disease: A Novel Cell-Free Therapeutic Strategy and Diagnostic Biomarker

Wang X, Yang F, Chen P, Yang M, Deng Y, Zhan Z.

Int J Nanomedicine. 2025 Dec 3;20:14375-14391. doi: 10.2147/IJN.S556625. eCollection 2025.

Potential beneficial effects of PD-1/PD-L1 blockade in Alzheimer's disease: a systematic review and meta-analysis of preclinical and clinical studies

Yoon J, Ha H, Lee HW, Kim S, Yu YM, Chun H.

Mol Psychiatry. 2026 Feb;31(2):1156-1166. doi: 10.1038/s41380-025-03413-2. Epub 2025 Dec 15.

Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials

Abushakra S, Doraiswamy PM, Hey JA, Tosun D, Barkhof F, Barakos J, Petrella J, Kesslak JP, Power A, Sabbagh M, Porsteinsson A, Cohen S, Gauthier S, Ritchie C, Watson D, McSweeney E, Boada M, Liang E, Bracoud L, McLaine R, Flint S, Schaefer JF, Yu J, Bray M, Hendrix S, Dickson S, Durrant A, Albayrak A, Tolar M.

CNS Drugs. 2026 Feb;40(2):199-214. doi: 10.1007/s40263-025-01251-y. Epub 2025 Dec 1.

Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid-beta drugs in Alzheimer's disease: a Bayesian meta-analysis

Ren S, Singh J, Gsteiger S, Cogley C, Reed B, Abrams KR, Dawoud D, Owen RK, Tappenden P, Quinn TJ, Bujkiewicz S.

J Comp Eff Res. 2026 Jan;15(1):e250095. doi: 10.57264/cer-2025-0095. Epub 2025 Dec 2.

PDE5 Inhibitors as Modulators of Alzheimer's-Associated Inflammation and Oxidative Stress: A Meta-Analytical Assessment of Preclinical Studies

Uppuluri CT, Prasad YSKV, Asadi K, Kumari TP, Pelluri R, Chakravarthi G, Nalluri BN, Gurram PC.

Mol Neurobiol. 2025 Dec 23;63(1):322. doi: 10.1007/s12035-025-05635-5.

Exploring precision medicine by utilizing individual genetic information for the management of Alzheimer's disease

Kanda A, Rani A, Mazumder A.

Pharmacogenomics. 2025 Jul-Aug;26(10-12):455-474. doi: 10.1080/14622416.2025.2560296. Epub 2025 Sep 15.

Examining the role of antioxidant supplementation in mitigating oxidative stress markers in Alzheimer's disease: a comprehensive review

Jawad M, Uthirapathy S, Altalbawy FMA, Oghenemaro EF, Rizaev J, Lal M, Eldesoqui M, Sharma N, Pramanik A, Al-Hamairy AK.

Inflammopharmacology. 2025 Feb;33(2):573-592. doi: 10.1007/s10787-024-01622-9. Epub 2024 Dec 19.

Critical nodes in precision diagnosis and treatment of Alzheimer's disease: exploration of multidimensional biomarkers and prospects for targeted intervention

Zuo Y, Ding X, Sun Y, Wang L, Song Y, Zhao Z, Liu C.

J Neurol Sci. 2025 Dec 15;479:123734. doi: 10.1016/j.jns.2025.123734. Epub 2025 Oct 28.

Alzheimer's disease diagnosis and treatment: From pathophysiological insights to therapeutic advances in the era of precision neurology (2025 review)

Kim M, Kwon H, Sohn S, Lee WJ, Cho K, Kim GW.

J Alzheimers Dis. 2026 Jan;109(1):17-33. doi: 10.1177/13872877251391820. Epub 2025 Oct 29.

The neuroinflammatory role of microRNAs in Alzheimer's disease: pathological insights to therapeutic potential

Liu W, Rao X, Sun W, Chen X, Yu L, Zhang J, Chen J, Zheng X.

Mol Cell Biochem. 2025 May;480(5):2689-2706. doi: 10.1007/s11010-024-05164-0. Epub 2024 Nov 20.

Integrating artificial intelligence with small molecule therapeutics and precision medicine for neurochemical understanding of Alzheimer's diseases

Alshehri ZS.

Neuroscience. 2025 Nov 1;586:44-57. doi: 10.1016/j.neuroscience.2025.08.055. Epub 2025 Sep 18.

Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer's Disease

Hey JA, Yu JY, Abushakra S, Schaefer JF, Power A, Kesslak P, Paul J, Tolar M.

Clin Pharmacokinet. 2025 Mar;64(3):407-424. doi: 10.1007/s40262-025-01482-8. Epub 2025 Feb 5.

Precision exercise in older adults with early Alzheimer's disease: The study protocol of the FIT-AD Sequential, Multiple Assignment, Randomized Trial (SMART)

Yu F, Todd M, Salisbury D, Maxfield M, Pruzin J, Joseph RP, Su Y, Li D, Baena E, Coon D.

Trials. 2025 Oct 15;26(1):416. doi: 10.1186/s13063-025-09040-0.

Association of dipeptidyl peptidase-4 with Alzheimer's disease: A new therapeutic prospect

Wang X, Chen L, Li W, He Z, Jiang H.

J Alzheimers Dis. 2025 Jan;103(2):319-332. doi: 10.1177/13872877241304673. Epub 2025 Jan 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias